Relief Therapeutics Holding AG (RLFTF) Stock Makes an Interesting Move: Are You Excited?

This morning many investors are going to be looking into stocks that recorded considerable gains last week and by that token, it is likely that the Relief Therapeutics Holding AG (OTCMKTS:RLFTF) stock is going to be one of those. The stock recorded gains of 25.50% this past Friday and ended the week with cumulative gains of as much as 57%.

Hence, it might be a good idea to actually keep an eye on the Relief stock this morning. The rally in the stock was brought about by a press release from the company’s collaboration partner NRx Pharmaceuticals last week. In the press release, the company provided information about a key milestone regarding aviptadil, the product on which the two companies are working.

NRx revealed that a commercial formulation of aviptadil that could be put to intravenous use had been validated. That is a major development since the company will now start preparing for industrial-scale manufacturing of the product. It was also noted that the aviptadil that is going to be commercially manufactured will also have the stability of a year or more as long as it is stored in ideal conditions.

On the other hand, NRx has also managed to boost its manufacturing capacity and is in a position to boost the manufacturing lot size of aviptadil by 30 to 50 times. It was a major development and it was no surprise that the Relief Therapeutics stock moved in such a big way. It remains to be seen if the stock can continue to add to its gains today.

Relief Therapeutics Holding AG (RLFTF) Stock Makes a Strong Comeback: What Next?

In recent times many biopharmaceutical companies have come into focus among investors in a big way and one of those is Relief Therapeutics Holding AG (OTCMKTS:RLFTF).

The stock has come into sharp focus already after a key announcement from the company this morning and soared by as much as 29% at the time of writing. This morning the company announced that the parent’s company of NRx Pharmaceuticals Inc, its collaboration partner, sent out a press release on Monday with regards to the considerable effect that aviptadil had in preventing the rise in cytokines in critically ill COVID 19 patients. It is a significant development for Relief Therapeutics and hence, the strong rally in the stock is perhaps understandable.

As per the press release from NRx Pharmaceuticals’ parent company, the data with regards to cytokine was collected from the Phase 2b/3 trial of aviptadil. During the course of this trial, the response in patients who had been administered with aviptadil were compared to those who had been treated with a placebo.

In addition to that, NRx Pharmaceuticals also announced that these findings were handed over to the United States Food and Drug Administration. The data was handed over as part of a supplement to its existing Emergency Use Authorization with the agency. Additionally, NRx Pharmaceuticals also noted that it has been cooperating with regard to any requests for additional information from the FDA. All this certainly bodes well for Relief Therapeutics, which has to collaborate with NRx on this project and it remains to be seen if the stock continues to add to its gains through the rest of the week.

Skip to content